Johnson Pharmacare Limited announced the appointment of Ms. Parul Agrawal as Additional Non-Executive & Independent Director following its board meeting held on February 13, 2026. The appointment was made pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Board Meeting Details

The board meeting was conducted on Friday, February 13, 2026, commencing at 12:15 P.M. and concluding at 12:45 P.M. The primary agenda focused on the appointment of Ms. Parul Agrawal as Additional Non-Executive & Independent Director with immediate effect.

Director Profile and Qualifications

Ms. Parul Agrawal brings professional expertise as a Company Secretary to strengthen the board's composition. The appointment aligns with corporate governance requirements and enhances the company's independent oversight capabilities.

Regulatory Compliance and Declarations

The appointment complies with SEBI Master Circular requirements and Schedule III of SEBI LODR Regulations. Ms. Agrawal has submitted a comprehensive non-debarment declaration confirming her eligibility to hold the director position.

The company has formally notified the Bombay Stock Exchange Limited regarding this appointment under scrip code 532154 with ISIN INE560F01022. Johnson Pharmacare Limited, incorporated in Gujarat with its registered office in Ahmedabad, continues to strengthen its governance framework through strategic board appointments that enhance oversight and compliance capabilities.

Johnson Pharmacare Limited announced its unaudited standalone financial results for the quarter ended 31st December, 2025, during a board meeting held on 14th February, 2026. The pharmaceutical company continues to face operational challenges with no revenue generation and mounting losses.

Financial Performance Overview

The company's financial performance for Q3 FY26 shows continued losses across all operational metrics. Johnson Pharmacare reported zero revenue from operations for the current quarter, consistent with previous quarters.

Expense Analysis

The company's expense structure for Q3 FY26 reveals significant increases across multiple categories compared to the previous quarter.

Finance costs emerged as the largest expense component at 4.01 lakhs for the current quarter, while other expenses contributed 2.18 lakhs. Employee benefits expense decreased to 0.21 lakhs from 0.30 lakhs in the previous quarter.

Nine-Month Performance

For the nine months ended 31st December, 2025, Johnson Pharmacare recorded a cumulative loss of 12.34 lakhs compared to 7.06 lakhs in the corresponding period of the previous year. Total expenses for the nine-month period stood at 12.34 lakhs, with other expenses accounting for 7.25 lakhs, finance costs at 4.28 lakhs, and employee benefits at 0.81 lakhs.

Share Capital and Earnings Per Share

The company maintains a paid-up equity share capital of 5,500.00 lakhs with a face value of Re. 1 per share. Basic and diluted earnings per share for continuing operations stood at (0.00) for Q3 FY26, Q2 FY26, and Q3 FY25.

Regulatory Compliance

The board also addressed compliance with Regulation 32 of SEBI (LODR) Regulations, 2015, confirming its non-applicability as the company has not issued shares through rights issue, preferential allotment, or any other issue during the quarter ended 31st December, 2025. The results were approved during a board meeting held at the company's registered office in Ahmedabad, Gujarat, under the chairmanship of Additional Director Rajender Parsad.